Связь между степенью тяжести течения заболевания и системным воспалением у пациентов с дилатационной кардиомиопатией
Аннотация
Цель. Изучить взаимосвязь между клинико-гемодинамическими показателями и маркерами воспаления (С-реактивный белок, IL-6, TNF-α) у пациентов с дилатационной кардиомиопатией.
Материалы и методы. В исследование были включены 42 пациента (38,5±1,2 года) с дилатационной кариомиопатией и сердечной недостаточностью II–IV ФК по NYHA. Пациенты были разделены на две группы: I группа – ФК II (n=12) и II группа – ФК III–IV (n=30).
Результаты. С увеличением тяжести сердечной недостаточности (ФК III–IV) у пациентов отмечено повышение уровней С-реактивного белка (7,6±1,1 мг/л и 4,1±0,6 мг/л, p<0,05), IL-6 (7,5±0,8 пг/мл и 4,6±0,2 пг/мл, p<0,01) и TNF-α (8,1±0,9 пг/мл и 5,6±0,7 пг/мл, p<0,05) в сыворотке крови, что коррелировало с дилатацией левого желудочка (КДР 58±1 мм, p<0,05) и снижением фракции выброса (34,7±1,8%, p<0,05).
Заключение. Маркеры воспаления имеют важное диагностическое значение при оценке тяжести и прогноза ДКМП.
Об авторах
Список литературы
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al. ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503–3626.
Elliott P, Andersson B, Arbustini E. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29: 270–276.
Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P et al. ; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2010; 31: 2715–2726.
Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC working group on myocardial and pericardial diseases. Eur Heart J 2013; 34: 1448–1458.
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016; 37: 1850–1858.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2021; 42: 1554–1568.
Arbustini E, Behr ER, Carrier L, van Duijn C, Evans P, Favalli V et al. Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. Eur Heart J 2022; 43: 1901–1916.
Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390(10092):400–414. https://doi.org/10.1016/S0140-6736(16)31713-5.
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–276.
Seferovic PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, Felix SB. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553–576. https://doi.org/10.1002/ejhf.1461.
AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Th.McDonagh, M. Metra. https://doi.org/10.15829/1560-4071-2023-5168.
Belenkov Yu.N., Nasonov E.L., Samsonov M.Yu., Ageev F.T., Mareev V.Yu. // Heart Failure. 2000. Vol. 4. pp. 135–138.
Dinarello C.A. // Cytokine Growth Factor Reviews. 1997. V. 8 (4). P. 253–265.
Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159–176. https://doi.org/10.1161/CIRCRESAHA.116.308030.
Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803–818. https://doi.org/10.1161/CIRCRESAHA.117.310221.
Wilson HM, Cheyne L, Brown PAJ, Kerr K, Hannah A, Srinivasan J, Duniak N, Horgan G, Dawson DK. Characterization of the myocardial inflammatory response in acute stress-induced (Takotsubo) cardiomyopathy. JACC Basic Transl Sci. 2018;3:766–778. https://doi.org/10.1016/j.jacbts.2018.08.006.
Shao Y., Redfors B., Scharin Tang M., Mollmann H., Troidl C., Szardien S. et al. Novel rat model reveals important roles of -adrenoreceptors in stress-induced cardiomyopathy. International Journal of Cardiology. 2013; 168(3):1943-50. https://doi.org/10.1016/j.ijcard.2012.02.092.
Sachdeva J., Dai W., Kloner R.A. Functional and Histological Assessment of an Experimental Model of Takotsubo‘s Cardiomyopathy. Journal of American Heart Association. 2014;3(3):e000921. https://doi.org/10.1161/JAHA.114.000921.
Ishikura F., Takano Y., Ueyama T. Acute effects of beta-blocker with intrinsic sympathomimetic activity on stress-induced cardiac dysfunction in rats. Journal of Cardiology. 2012;60(6): 470-4. https://doi.org/10.1016/j.jjcc.2012.07.004.
Haggendal J., Johansson G., Jonsson L., Thoren-Tolling K. Effect of Propranolol on Myocardial Cell Necroses and Blood Levels of Catecholamines in Pigs Subjected to Stress. Acta Pharmacologica et Toxicologica. 2009;50(1): 58-66. https://doi.org/10.1111/j.1600-0773.1982.tb00940.x.
Kühl U, Noutsias M, Seeberg B, Schultheiss HP. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996;75:295–300.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor- alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711. https://doi.org/10.1161/01.cir.93.4.704.
Belenkov Yu.N., Ageev F.T., Mareev V.Yu. Neurohormones and cytokines in heart failure: a new theory of an old disease? Journal Heart Failure, 2000: 1(4), 35–38.
Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625–631. https://doi.org/10.1 161/CIRCULATIONAHA.107.759191.
Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 2004;164:665–677. https://doi.org/10.1016/S0002-9440(10)63154-9.
Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 1997;81:664–671. https://doi.org/10.1161/01.res.81.5.664.
Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30:215–223. https://doi.org/10.1006/jmcc.1997.0 592.
Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 1997;81:664–671. https://doi.org/10.1161/01.res.81.5.664.
Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca(2+)/calmodulin-dependent protein kinase II delta signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation. 2018;138:2530–2544. https://doi.org/10.1161/CIRCULATIONAHA.118.034621.
Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S’, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594–604. https://doi.org/10.1161/CIRCULATIONAHA.110.982777.
Murphy SP, Kakkar R, McCarthy CP, Januzzi JL., Jr Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324–40. https://doi.org/10.1016/j.jacc.2020.01.014.
Liu S.J., Zhou W., Kennedy R.H. Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1brta in rat ventricular myocytes. Am J Physiol. 1999; 276(1):H141-8. https://doi.org/10.1152/ ajpheart.1999.276.1.H141.
Tatsumi T., Matoba S., Kawahara A. et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. Pflugers Arch. 2002; 35(5): 1338-46. https://doi.org/10.1016/s0735-1097(00)00526-x.
Aleksova A., Beltrami A.P., Carriere C. et al. Interleukin-1 levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy. Oncotarget. 2017; 8(15):25131-25140. https://doi.org/10.18632/oncotarget.15349.
Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19:819–824. https://doi.org/10.1016/s1053-2498(00)00173-x.
Raymond RJ, Dehmer GJ, Theoharides TC, Deliargyris EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J. 2001;141(3):435–8. https://doi.org/10.1 067/mhj.2001.113078.
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–91. https://doi.org/10.1161/01.CIR.0000057810.48709.F6.
Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte–derived interleukin-6. Circulation. 1995;91(5):1520–4. https://doi.org/10.1161/01.CIR. 91.5.1520.
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom- guided heart failure therapy: the trial of intensified vs Standard Medical Therapy in Elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. https://doi.org/10.1 001/jama.2009.2.
Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-2760.
Deftereos C, Giannopoulos G, Panagopoulos V, Bouras G, Raisakis R, Koskinas K, et al. Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure. JACC Heart Fail. 2014;2(2):131-137.
Pascual-Figal D, Núñez J, Pérez-Martínez MT, González-Juanatey JR, Taibo-Urquía M, Llácer-Borrá P, et al. Colchicine in acutely decompensated heart failure: the COLICA trial. Eur Heart J. 2024;45(45):4826- 4836.
Xuan Sun et al., Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2-Mediated Suppression of NLRP3 Inflammasome Activation. JAHA, Volume 11, Number 13, https://doi.org/10.1161/JAHA.122.02 5266.
Copyright (c) 2025 Т.А. Абдуллаев, М.М. Рахматов, Х.А. Гуломов (Автор)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.